MX352892B - Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. - Google Patents
Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.Info
- Publication number
- MX352892B MX352892B MX2014001717A MX2014001717A MX352892B MX 352892 B MX352892 B MX 352892B MX 2014001717 A MX2014001717 A MX 2014001717A MX 2014001717 A MX2014001717 A MX 2014001717A MX 352892 B MX352892 B MX 352892B
- Authority
- MX
- Mexico
- Prior art keywords
- yeast
- immunotherapeutic compositions
- muc1 immunotherapeutic
- mucl
- mucin
- Prior art date
Links
- 230000001024 immunotherapeutic effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000007298 Mucin-1 Human genes 0.000 abstract 2
- 108010008707 Mucin-1 Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una composición inmunoterapéutica de Levadura MUC1, caracterizada porque comprende: a) un vehículo de levadura; y b) al menos un antígeno MUC1 expresado por el vehículo de levadura, en donde el antígeno MUC1 comprende una secuencia de aminoácidos que es al menos 95% idéntica a la SEQ ID NO; 25 o a las posiciones 92-566 de la SEQ ID NO: 25, y en donde el antígeno MUC1 comprende 2, 3, 4, 5, 6, 7, 8, 9, 10 u 11 de los siguientes aminoácidos L184, Y232, L233, V240, Y241, L242, Y483, V497, l535, F536 e Y551.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161524407P | 2011-08-17 | 2011-08-17 | |
PCT/US2012/051299 WO2013025972A1 (en) | 2011-08-17 | 2012-08-17 | Yeast-muc1 immunotherapeutic compositions and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014001717A MX2014001717A (es) | 2014-04-14 |
MX352892B true MX352892B (es) | 2017-12-13 |
Family
ID=47715495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014001717A MX352892B (es) | 2011-08-17 | 2012-08-17 | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. |
Country Status (13)
Country | Link |
---|---|
US (3) | US9533031B2 (es) |
EP (1) | EP2744918A4 (es) |
JP (4) | JP6122007B2 (es) |
KR (1) | KR102049928B1 (es) |
CN (3) | CN109010809A (es) |
AU (3) | AU2012296425B2 (es) |
BR (1) | BR112014003477B1 (es) |
CA (1) | CA2844500C (es) |
IL (2) | IL230863B (es) |
MX (1) | MX352892B (es) |
RU (2) | RU2017143985A (es) |
SG (1) | SG10201607663YA (es) |
WO (1) | WO2013025972A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2725450T3 (es) | 2007-07-02 | 2019-09-24 | Etubics Corp | Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples |
EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
US8877205B2 (en) | 2011-02-12 | 2014-11-04 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis B infection |
KR102046449B1 (ko) | 2011-03-17 | 2019-11-19 | 글로브이뮨 | 효모-브라큐리 면역요법 조성물 |
CN103732250A (zh) | 2011-06-14 | 2014-04-16 | 全球免疫股份有限公司 | 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法 |
CA2844500C (en) * | 2011-08-17 | 2022-05-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
US10138271B2 (en) | 2012-01-03 | 2018-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Native and agonist CTL epitopes of the MUC1 tumor antigen |
EP2864792A1 (en) | 2012-06-26 | 2015-04-29 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
US10507235B2 (en) | 2013-03-19 | 2019-12-17 | Globeimmune, Inc. | Yeast-based immunotherapy for Chordoma |
TWI728239B (zh) | 2013-03-26 | 2021-05-21 | 美商環球免疫公司 | 治療或預防人類免疫缺乏病毒感染之組合物及方法 |
TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
EP3412304A3 (en) | 2013-10-23 | 2019-03-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
US10799567B2 (en) | 2014-04-11 | 2020-10-13 | Globeimmune, Inc. | Yeast-based immunotherapy and type I interferon sensitivity |
EP3236995A4 (en) | 2014-12-23 | 2018-07-18 | University of Maryland, Baltimore | Muc1 decoy peptides for treatment and prevention of bacterial infections |
CN113456812A (zh) * | 2015-01-09 | 2021-10-01 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
US10695417B2 (en) | 2015-01-09 | 2020-06-30 | Etubics Corporation | Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
EP4140492A1 (en) | 2015-04-21 | 2023-03-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
EP3331552B1 (en) * | 2015-08-03 | 2021-01-27 | Globeimmune, Inc. | Modified yeast-brachyury immunotherapeutic compositions |
EP3383427A4 (en) * | 2015-12-04 | 2019-11-27 | Mayo Foundation for Medical Education and Research | METHODS AND VACCINES FOR INDUCING IMMUNE RESPONSES OF MULTIPLE DIFFERENT CMH MOLECULES |
WO2017120204A2 (en) | 2016-01-05 | 2017-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
TWI654302B (zh) * | 2016-01-19 | 2019-03-21 | 輝瑞股份有限公司 | 癌症疫苗 |
WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
CN109563521A (zh) | 2016-03-24 | 2019-04-02 | 河谷细胞有限公司 | 用于新表位呈递的序列排列和序列 |
CA3061240C (en) | 2017-04-24 | 2024-01-16 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
WO2019222073A1 (en) * | 2018-05-15 | 2019-11-21 | Globeimmune, Inc. | Lysates of recombinant yeast for inducing cellular immune responses |
US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
CA3175772A1 (en) * | 2020-04-17 | 2021-10-21 | Gerard Karsenty | Methods, compositions and uses thereof for reversing sarcopenia |
CN113214210B (zh) | 2021-05-10 | 2022-03-04 | 合肥立方制药股份有限公司 | 一种二氢槲皮素的制备方法 |
CN113185485B (zh) | 2021-05-10 | 2022-03-04 | 合肥立方制药股份有限公司 | 一种二氢槲皮素的半合成方法 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
AU727308B2 (en) | 1997-02-24 | 2000-12-07 | Dana-Farber Cancer Institute | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
DE19758400A1 (de) | 1997-12-30 | 1999-07-01 | Max Delbrueck Centrum | Tumorvakzine für MUC1-positive Karzinome |
JP4409097B2 (ja) | 1998-12-09 | 2010-02-03 | アメリカ合衆国 | 複数の共刺激分子を発現する組換えベクターおよびその利用 |
DE19906615A1 (de) * | 1999-02-17 | 2000-09-28 | Hanisch Franz Georg | Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung |
JP2003510094A (ja) * | 1999-09-08 | 2003-03-18 | トランジェーヌ、ソシエテ、アノニム | Muc−1由来のペプチド |
DE10006753A1 (de) | 2000-02-15 | 2001-08-16 | Zeiss Carl | Dreh-Schwenkeinrichtung für den Tastkopf eines Koordinatenmeßgerätes |
US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
ES2260078T3 (es) | 2000-04-06 | 2006-11-01 | Seer Pharmaceuticals, Llc. | Sistema de administracion microbiana. |
AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
DE60313163T2 (de) * | 2002-06-11 | 2008-01-03 | Glaxosmithkline Biologicals S.A. | Immunogene zusammensetzungen |
AU2003251531A1 (en) * | 2002-06-14 | 2003-12-31 | Diadexus, Inc. | Compositions and methods relating to breast specific genes and proteins |
US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
KR101164509B1 (ko) * | 2002-12-16 | 2012-07-10 | 글로브이뮨 | 면역 요법으로서의 효모계 백신 |
US7696306B2 (en) | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
ES2623812T3 (es) * | 2003-11-12 | 2017-07-12 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Vectores a medida para tratar y prevenir cáncer pancreático |
WO2005051991A2 (en) * | 2003-11-24 | 2005-06-09 | Sidney Kimmel Cancer Center | Mucin antigen vaccine |
JP2008504219A (ja) * | 2003-12-11 | 2008-02-14 | シドニー キンメル キャンサー センター | 抗原に対する免疫を生じさせる方法 |
US8828957B2 (en) * | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
EP1697399B1 (en) | 2003-12-12 | 2016-11-23 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
AU2006268333B2 (en) * | 2005-07-11 | 2012-06-14 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
CA2637947A1 (en) * | 2006-01-23 | 2007-07-23 | Recopharma Ab | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
SG10201402236VA (en) | 2006-02-02 | 2014-08-28 | Globeimmune Inc | Yeast-based vaccine for inducing an immune response |
BRPI0709340A2 (pt) | 2006-03-27 | 2013-04-16 | Globeimmune Inc | mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma |
CA2676783C (en) | 2007-02-02 | 2016-04-05 | Globeimmune, Inc. | Improved methods for producing yeast-based vaccines |
JP5579451B2 (ja) | 2007-03-19 | 2014-08-27 | グローブイミューン,インコーポレイテッド | ガンのための標的化治療の変異性回避の標的化アブレーションのための組成物 |
CA2704232C (en) | 2007-11-08 | 2017-05-02 | Dana-Farber Cancer Institute, Inc. | Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28 |
EP2331125A4 (en) | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
EP2352508B1 (en) * | 2008-10-17 | 2014-04-02 | Dana-Farber Cancer Institute, Inc. | Muc-1 cytoplasmic domain peptides as inhibitors of cancer |
WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
AU2010236206B2 (en) * | 2009-04-17 | 2016-10-20 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
AU2010291985B2 (en) | 2009-09-14 | 2016-05-05 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
EP2547792A4 (en) | 2010-03-14 | 2013-11-27 | Globeimmune Inc | PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY |
WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
US8877205B2 (en) | 2011-02-12 | 2014-11-04 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis B infection |
KR102046449B1 (ko) | 2011-03-17 | 2019-11-19 | 글로브이뮨 | 효모-브라큐리 면역요법 조성물 |
CN103732250A (zh) | 2011-06-14 | 2014-04-16 | 全球免疫股份有限公司 | 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法 |
CA2844500C (en) | 2011-08-17 | 2022-05-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
-
2012
- 2012-08-17 CA CA2844500A patent/CA2844500C/en active Active
- 2012-08-17 CN CN201810735110.0A patent/CN109010809A/zh active Pending
- 2012-08-17 RU RU2017143985A patent/RU2017143985A/ru not_active Application Discontinuation
- 2012-08-17 BR BR112014003477-0A patent/BR112014003477B1/pt active IP Right Grant
- 2012-08-17 EP EP12824638.6A patent/EP2744918A4/en active Pending
- 2012-08-17 CN CN201280051154.2A patent/CN104024429B/zh active Active
- 2012-08-17 MX MX2014001717A patent/MX352892B/es active IP Right Grant
- 2012-08-17 KR KR1020147006872A patent/KR102049928B1/ko active IP Right Grant
- 2012-08-17 RU RU2014109741A patent/RU2642300C2/ru active
- 2012-08-17 AU AU2012296425A patent/AU2012296425B2/en active Active
- 2012-08-17 JP JP2014526241A patent/JP6122007B2/ja active Active
- 2012-08-17 SG SG10201607663YA patent/SG10201607663YA/en unknown
- 2012-08-17 CN CN202210208007.7A patent/CN114617958A/zh active Pending
- 2012-08-17 WO PCT/US2012/051299 patent/WO2013025972A1/en active Application Filing
-
2013
- 2013-03-14 US US13/803,757 patent/US9533031B2/en active Active
-
2014
- 2014-02-06 IL IL230863A patent/IL230863B/en active IP Right Grant
-
2016
- 2016-11-22 US US15/358,797 patent/US10188714B2/en active Active
-
2017
- 2017-03-30 JP JP2017067243A patent/JP6306238B2/ja active Active
- 2017-10-18 AU AU2017248462A patent/AU2017248462B2/en active Active
-
2018
- 2018-02-14 IL IL257533A patent/IL257533B/en active IP Right Grant
- 2018-03-07 JP JP2018040308A patent/JP6571822B2/ja active Active
- 2018-12-06 US US16/211,492 patent/US11065318B2/en active Active
-
2019
- 2019-08-08 JP JP2019145946A patent/JP2019194261A/ja active Pending
-
2020
- 2020-01-08 AU AU2020200137A patent/AU2020200137B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX352892B (es) | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. | |
MX2013010475A (es) | Composiciones inmunoterapeuticas de levadura-brachyuri. | |
PH12014502697B1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
MY184101A (en) | Indoles | |
MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
EP2714081A4 (en) | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT | |
IN2012DN03883A (es) | ||
IN2012DN02081A (es) | ||
MX2014009289A (es) | Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer. | |
MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
MX370721B (es) | Compuestos y composiciones novedosas para atacar las células madre del cáncer. | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MX2015007097A (es) | Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer. | |
WO2013022991A3 (en) | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer | |
MY157341A (en) | Methods and compositions for treating lung cancer | |
MX354988B (es) | Formulaciones de anticuerpo y metodos. | |
MX367393B (es) | Composiciones antifungicas para el tratamiento de piel y uñas. | |
WO2012017321A3 (en) | Treatment for dyslipidemia | |
WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists | |
AU2016204389A1 (en) | Kinase inhibitors for the treatment of cancer | |
MX2021008225A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. | |
MX2013000539A (es) | Nuevas formulaciones de analogos 14-epi de la vitamina d. | |
MX2011010046A (es) | Derivados de diaminopteridina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |